pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

philogen PRESS RELEASE ARCHIVE

May 30, 2023

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand USA - English USA - English APAC - English USA - español USA - Deutsch USA - Français

Dec 1, 2022

Philogen Provides Corporate Update

Jan 13, 2021

Philogen Announces the Completion of a Second Interim Analysis of Its Phase III Clinical Program With Nidlegy for the Treatment of Melanoma

Oct 8, 2020

Philogen Announces Publication of Malignant Brain Tumor Study Results in Science Translational Medicine

Jun 26, 2020

Philogen Received Clinical Trial Authorisation With Nidlegy in Nonmelanoma Skin Cancer English English

Jun 24, 2020

Philogen Received Combination Pack Approval for Nidlegy USA - English India - English

Apr 28, 2020

Philogen Announces Option Exercise by Janssen

May 13, 2019

Philogen Announces €62 Million Financing Round

Jan 23, 2019

Philogen Announces Drug Discovery Collaboration With Johnson and Johnson Innovation

Jan 23, 2019

Philogen Announces Collaboration

Jan 23, 2019

Philogen Announces Collaboration With Celgene

Oct 12, 2017

Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma

Aug 25, 2017

Philogen Announces Research Collaboration with Servier in the Field of DNA-Encoded Chemistry

Jul 20, 2017

Philogen Enters into Multi-Target Research Agreement with Boehringer Ingelheim in the Field Of DNA-Encoded Chemistry

Oct 28, 2016

Philogen SpA Receives Orphan Drug Designation for the Treatment of Soft Tissue Sarcoma France - Français Deutschland - Deutsch USA - English España - español

Aug 3, 2016

Philogen Announces Collaboration With Johnson & Johnson Innovation

Feb 15, 2016

Philogen Announces Expanded Research and Development Agreement with AbbVie

Jan 21, 2016

Philogen Announces Exercise of Options Within the License Agreement With Pfizer Inc. for the Development and Potential Commercialization of Multiple Antibody Drug Conjugates (ADCs) and Targeted Technologies

Jan 21, 2016

Philogen Announces Commencement of Phase III Pivotal Trial in Melanoma

Nov 29, 2012

Actinium Pharmaceuticals and Philogen S.p.A. Announce Start of Pre-Clinical Development of an Alpha Therapy Based Antiangiogenesis Program

Aug 9, 2012

Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program

Google Analytics Alternative